HZRM Haemophilie-Zentrum Rhein Main GmbH

Research site

Germany Stresemannallee 15, Sachsenhausen, 60596 Frankfurt, Germany

4 trials recruiting
Hereditary angioedema · Factor VIII deficiency · Hereditary angioedema with C1 esterase inhibitor deficiency
Adults and children

About Specializations

HZRM Haemophilie-Zentrum Rhein Main GmbH in Frankfurt, Germany specialises in clinical trials of conditions such as Hereditary angioedema, Factor VIII deficiency, Hereditary angioedema with C1 esterase inhibitor deficiency, Synovitis, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Stresemannallee 15, Sachsenhausen60596 FrankfurtGermany

Open in maps ↗

Recruiting now: 4 trials
Conditions studied: 4

More sites in Frankfurt Germany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

10 clinical trials

Factor VIII deficiency+1

Recruiting

Efficacy of efanesoctocog alfa in reducing synovitis in patients with congenital hemophilia A – a multicenter, randomized, open‑label phase 3 trial

Registered drugNo placebo

Efficacy of efanesoctocog alfa in reducing synovitis in patients with congenital hemophilia A – a multicenter, randomized, open‑label phase 3 trial

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Efanesoctocog Alfa
Sponsor:GWT-Tud GmbH

Contact Research Centre

Hereditary angioedema

Recruiting

Study of deucrictibant tablets for prevention of hereditary angioedema attacks in adults and adolescents

InvestigationalNo placebo

Study of deucrictibant tablets for prevention of hereditary angioedema attacks in adults and adolescents

InvestigationalNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Deucrictibant
Sponsor:Pharvaris Netherlands B.V.

Contact Research Centre

Factor VIII deficiency

Recruiting

Study on Emicizumab and Drug Combination for Patients with Haemophilia A and FVIII Inhibitors

Registered drugNo placebo

Study on Emicizumab and Drug Combination for Patients with Haemophilia A and FVIII Inhibitors

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Emicizumab
Sponsor:Emory University

Contact Research Centre

Hereditary angioedema with C1 esterase inhibitor deficiency

Recruiting

Study on the Safety of Long-Term Use of Deucrictibant for Treating Hereditary Angioedema Attacks in Patients with C1-Inhibitor Deficiency

Registered drug

Study on the Safety of Long-Term Use of Deucrictibant for Treating Hereditary Angioedema Attacks in Patients with C1-Inhibitor Deficiency

Registered drug

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Deucrictibant
Sponsor:Pharvaris Netherlands B.V.

Contact Research Centre

Hereditary angioedema

Not recruiting

Safety Study of Switching from Current Treatment to Garadacimab in Patients Age 12 and Older with Hereditary Angioedema

InvestigationalNo placebo

Safety Study of Switching from Current Treatment to Garadacimab in Patients Age 12 and Older with Hereditary Angioedema

InvestigationalNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Garadacimab
Sponsor:CSL Behring LLC

Contact Research Centre

Factor VIII deficiency

Not recruiting

Study on Long-Term Effects of Efanesoctocog Alfa in Preventing Joint Bleeds in Patients with Hemophilia A

Registered drugNo placebo

Study on Long-Term Effects of Efanesoctocog Alfa in Preventing Joint Bleeds in Patients with Hemophilia A

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Efanesoctocog Alfa
Sponsor:Swedish Orphan Biovitrum AB (publ)

Contact Research Centre

Hereditary angioedema

Not recruiting

Study of Deucrictibant Extended-Release Tablets for Prevention of Hereditary Angioedema Attacks in Adults and Adolescents

Registered drug

Study of Deucrictibant Extended-Release Tablets for Prevention of Hereditary Angioedema Attacks in Adults and Adolescents

Registered drug

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Deucrictibant
Sponsor:Pharvaris Netherlands B.V.

Contact Research Centre

Hereditary angioedema with C1 esterase inhibitor deficiency

Not recruiting

Long-term Safety Study of KVD900 for Treating Angioedema Attacks in Adolescents and Adults with Hereditary Angioedema Type I or II

InvestigationalNo placebo

Long-term Safety Study of KVD900 for Treating Angioedema Attacks in Adolescents and Adults with Hereditary Angioedema Type I or II

InvestigationalNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Sebetralstat
Sponsor:Kalvista Pharmaceuticals Limited

Contact Research Centre

Hereditary angioedema

Not recruiting

Long-term safety study of garadacimab (CSL312) for prevention of hereditary angioedema attacks

InvestigationalNo placebo

Long-term safety study of garadacimab (CSL312) for prevention of hereditary angioedema attacks

InvestigationalNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Garadacimab
Sponsor:CSL Behring LLC

Contact Research Centre

Hereditary angioedema

Not recruiting

Study on the Safety and Effects of Garadacimab for Preventing Hereditary Angioedema in Children Aged 2 to 11

InvestigationalNo placebo

Study on the Safety and Effects of Garadacimab for Preventing Hereditary Angioedema in Children Aged 2 to 11

InvestigationalNo placebo

Germany

Participants:0–17 years
Substances:Garadacimab
Sponsor:CSL Behring LLC

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites